Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
PFE or LLY: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 29'th May 2025
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better val
Are Investors Undervaluing Pfizer (PFE) Right Now?
10:46am, Thursday, 29'th May 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
10:06am, Thursday, 29'th May 2025
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
10:04am, Thursday, 29'th May 2025
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initia
5 Rock-Solid Dividend Stocks Under $50 With Room to Run
08:50am, Thursday, 29'th May 2025
Looking for high-yield dividend stocks below $50? Here are the top five.
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
10:12pm, Tuesday, 27'th May 2025
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Managem
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Tuesday, 27'th May 2025
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
01:07am, Monday, 26'th May 2025
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature
Down 63%, Should You Buy the Dip on Pfizer?
08:45am, Saturday, 24'th May 2025
It's been a tough go for Pfizer (PFE 1.28%). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago.
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
04:51am, Saturday, 24'th May 2025
Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend.
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
04:11am, Saturday, 24'th May 2025
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again.
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
03:21pm, Friday, 23'rd May 2025
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Pfizer Stock Analysis: Buy, Sell, or Hold?
07:57am, Friday, 23'rd May 2025
Pfizer's (PFE -0.07%) management team is confident in its 2025 opportunities.
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
05:00pm, Thursday, 22'nd May 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
08:45am, Thursday, 22'nd May 2025
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
